The Global CD Antigen Cancer Therapy Market size was worth US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2022-2029).
CD markers are also known as CD antigens, specific types of molecules found on the surface of cells that help to differentiate one cell type. The initials "CD" stands for "cluster of differentiation," the nomenclature established in 1982. CD antigens can be used to detect the abnormal growth of cells known as a neoplasm. Neoplasms may be benign (noncancerous), malignant (cancerous), or precancerous, but, like any other cell, have CD markers that scientists can use to identify them. CD markers are crucial in cancer diagnosis, but they can also help identify which types of treatment may be most successful and measure how effective the treatment is by monitoring changes in the relevant CD markers. Moreover, researchers can create a type of defensive protein, known as a monoclonal antibody (mAb), which is matched to a specific CD antigen. These cloned antibodies mimic those produced by the body and can fight cancer in a treatment known as targeted immunotherapy. When injected into the body, mAbs can act in distinctive ways depending on their design:
Outside of the body, mAbs are commonly used in diagnosis to detect specific CD antigens in blood, tissue, or body fluid samples. Increasing prevalence of cancer cases are anticipated to drive the CD Antigen cancer market.
Source: DataM Intelligence Analysis (2020)
The global CD Antigen Cancer Therapy market growth is driven by the growing incidence of Cancer cases and changing lifestyle, Increasing demand for therapies with minimal adverse effects and advanced technological facilities, On-going clinical trials to develop newer therapy are among the key factors driving market growth.
Growing incidence of cancer cases, is expected to drive the global CD Antigen cancer therapy market growth.
As per the World Health Organisation (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of CD Antigen cancer therapies.
On-going Clinical Trials to develop new therapy, is expected to drive the global CD Antigen cancer therapy market growth.
The prevalence of cancer worldwide is driving many vendors in the market to develop novel therapies. For instance, Takeda ( Millennium Pharmaceuticals, Inc. ), in collaboration with Seagen Inc conducting Phase III trials to study response rate (ORR), lasting at least four months (ORR4), with brentuximab vedotin with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma [mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) ]compared to that achieved with therapy.
Major side effects of drugs is likely to hinder the market growth
On the contrary, side effects related to CD Antigens drugs in cancer therapy are weakness, burning eyes, slow heart rate, sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath, high blood sugar, ketoacidosis, low blood cell counts, liver problems, stomach problems. Short-acting versions of these drugs have been previously shown to be dangerous and now long-acting versions are being shown to be possibly dangerous as well. These factors restrict the market growth.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global CD Antigen Cancer Therapy market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Monoclonal Antibodies segment accounts largest share in the market, is expected to drive the market during forecast period.
Monoclonal antibody-based cancer treatment is one of the most successful therapeutic strategies for hematologic malignancies and solid tumors in the last 20 years. A monoclonal antibody used to treat cancer may block a receptor that cancer cells use to prevent the immune system from destroying the cancer cell, and blocking this receptor allows the immune system to recognize cancer cells and destroy them. For instance, In January 2020, Alderaan Biotechnology, a preclinical company focused on developing anti-CD25 monoclonal antibodies for cancer treatment, announced that it raised €18.5 million in Series A financing. Rituximab binds to a protein called CD20 on B cells type of white blood cells and some types of cancer cells, causing the immune system to kill them.
Antibody-drug conjugates are the immunotherapy agents that use the potential cytotoxic molecule combined with monoclonal antibodies through chemical linkers. In turn, it increases the ability of the drug to target specific tumor cells. For instance, ASN004 is an Antibody-Drug Conjugate (ADC) that selectively targets the 5T4 oncofetal antigen (trophoblast glycoprotein) widely expressed in malignant tumors is under Phase 1 trials.
Bispecific T-cell engagers (BiTEs) are artificial bispecific monoclonal antibodies investigated for use as anti-cancer drugs. They direct a host's immune system, specifically the T cells' cytotoxic activity, against cancer cells. BiTEs form a link between T cells and tumor cells. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis. For instance, BiTE, a registered trademark of Micromet AG, a fully owned subsidiary of Amgen Inc.
Based on End-User, the global small molecule targeted cancer therapy market is segmented into Hospitals, Cancer Research centers, clinics, others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.
Source: DataM Intelligence Analysis (2020)
North America is expected to hold a large market share in the global CD Antigen Cancer Therapy Market due to the growing incidence of cancer cases. The International Agency for Research on Cancer (IARC) claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel Anti-CD cancer drugs, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, In March 2019, AstraZeneca collaborated with Daiichi Sankyo company for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate and potential new targeted medicine for cancer treatment.
Source: DataM Intelligence Analysis (2020)
The Global CD-Antigen Cancer Therapy Market is quite competitive with some key competitors like АrуоGеn Віорhаrmа, Віосаd, Віоgеn Іdес, Сеlltrіоn, Gеnеntесh, Gеnmаb, Merck, Sandoz, Seattle Genetics, Inc, Eli Lilly the Company. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the market globally. For instance, under the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights. Takeda Pharmaceuticals has the right to commercialize ADCETRIS in the rest of the world.
Seattle Genetics Inc
Overview: Seattle Genetics is a US-based biotechnology company focusing on developing and commercializing innovative, empowered monoclonal antibody-based therapies to treat cancer. The company is headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics, Inc changes its name to Seagen Inc. to reflect the transformation of the company from its strong Seattle roots into a global operation.
Product Portfolio: As part of research and development activities for innovative drugs, the company focuses primarily on the monoclonal antibody therapies and antibody-drug conjugates.
Product- In 2017, ADCETRIS is approved in the U.S. for primary cutaneous ALCL or CD30-expressing mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
In 2020, TUKYSA® (tucatinib) was approved in the U.S. and other countries for certain HER2+ metastatic breast cancers combined with trastuzumab and capecitabine is third approved and first wholly-owned medicine.
The global CD-Antigen Cancer Therapy report would provide an access to an approx. market data 53 tables, 44 figures and 240 pages.
Get your free sample proposal with a single click!